Iovance Biotherapeutics (IOVA) PRER14A 19 Apr 23 Preliminary revised proxy Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2022
Document and Entity Information [Abstract]
Document Type	PRER14A
Entity Registrant Name	IOVANCE BIOTHERAPEUTICS, INC.
Entity Central Index Key	0001425205
Amendment Flag	true
Amendment Description	This revised proxy statement of Iovance Biotherapeutics, Inc. (the "Company") amends, restates and supersedes the preliminary proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 14, 2023 (the "original proxy statement"), which was filed in connection with the Company's 2023 Annual Meeting of Stockholders. This proxy statement is being filed: (1) to add the names of the director nominees in Proposal 1, (2) to include the proposed increase of the number of shares of common stock to be authorized for grant of equity awards under the Company's 2018 Equiy Incentive Plan, as amended, for Proposal No. 4 (3) to include the proposed increase of the number of shares of common stock to be authorized for grant of equity awards under the Company's 2020 Employee Stock Purchase Plan, as amended, for Proposal No. 5 and (4) to include the proposed increase of the number of authorized shares of common stock in the Company's Certificate of Incorporation, as amended, for Proposal No. 6. This revised proxy statement should be read in place of the original proxy statement, and amends, restates and supersedes the original proxy statement in all respects.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pay vs Performance Disclosure [Table]
Pay vs Performance [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Value of Initial Fixed ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $100 Investment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average SCT ​ Average CAP ​ ​ ​ ​ NASDAQ ​ ​ ​ ​ Company- ​ ​ SCT ​ CAP ​ SCT ​ CAP ​ Compensation ​ Compensation ​ Company ​ Biotech Index ​ ​ ​ ​ selected ​ ​ Compensation ​ Compensation ​ Compensation ​ Compensation ​ for Other ​ for Other ​ Total Share- ​ Total Share- ​ Net Loss ​ Finacial Perf. Year for CEO 1 ​ for CEO 1 for CEO 2 for CEO 2 NEOs NEOs holder Return holder Return ($M) Measure (a) ​ (b) ​ (c) ​ (d) ​ (e) ​ (f) ​ (g) ​ (h) ​ (i) ​ (j) ​ (k) 2022 ​ $ 5,259,100 ​ $ (173,208) ​ $ N/A ​ $ N/A ​ $ 2,159,230 ​ $ (50,500) ​ $ 23.08 ​ $ 113.65 ​ ​ (395.9) ​ $ — 2021 ​ $ 3,216,310 ​ $ 3,169,786 ​ $ 7,011,698 ​ $ (2,484,140) ​ $ 3,270,763 ​ $ (324,022) ​ $ 68.95 ​ $ 126.45 ​ ​ (342.3) ​ $ — 2020 ​ $ N/A ​ $ N/A ​ $ 9,039,400 ​ $ 22,045,076 ​ $ 2,593,418 ​ $ 5,003,997 ​ $ 167.61 ​ $ 126.42 ​ ​ (259.6) ​ $ — Columns (b), (d) and (f) . Reflects compensation amounts reported in the “Summary Compensation Table” (“SCT”) for our CEOs and average amount reported for our non-CEO NEOs, for the respective years shown. Our CEOs and non-CEO NEOs for each of these fiscal years are shown below: Year CEO Non-CEO NEOs 2022 Frederick G. Vogt, Ph.D., J.D. Friedrich Graf Finckenstein, M.D., Jean-Marc Bellemin, Igor Bilinsky, Ph.D. 2021 ​ Frederick G. Vogt, Ph.D., J.D. (effective June 18, 2021), Maria Fardis, Ph.D. (until June 18, 2021) Friedrich Graf Finckenstein, M.D., Jean-Marc Bellemin, Igor Bilinsky, Ph.D., Michael Swartzburg 2020 ​ Maria Fardis, Ph.D. ​ Frederick G. Vogt, Ph.D., J.D (as General Counsel), Friedrich Graf Finckenstein, M.D., Jean-Marc Bellemin, Michael Swartzburg ​ Columns (c), (e) and (g) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CAP ​ Average ​ CAP ​ CAP Average ​ CAP ​ Average ​ ​ Compensation ​ CAP ​ Compensation ​ Compensation CAP ​ Compensation ​ CAP ​ ​ for ​ Compensation ​ for ​ for Compensation ​ for ​ Compensation Adjustments CEO 1 for other NEOs CEO 1 CEO 2 for other NEOs CEO 2 for other NEOs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reported Summary Compensation Table Total ​ $ 5,259,100 ​ $ 2,159,230 ​ $ 3,216,310 ​ $ 7,011,698 $ 3,270,763 ​ $ 9,039,400 ​ $ 2,593,418 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deduction for amounts reported under Stock Awards and Option Awards columns in Summary Compensation Table for applicable fiscal year. ​ $ (3,872,500) ​ $ (1,185,030) ​ $ (2,463,502) ​ $ (6,729,775) $ (2,880,217) ​ $ (8,139,400) ​ $ (2,197,299) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Add back: The year-end fair value of any equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the fiscal year ​ $ 1,597,498 ​ $ 463,158 ​ $ 2,416,978 ​ $ — $ 1,548,311 ​ $ 17,391,380 ​ $ 3,771,653 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The change in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year ​ $ (1,408,496) ​ $ (558,816) ​ $ — ​ $ — $ (1,234,414) ​ $ 3,171,811 ​ $ 728,968 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For awards that are granted and vest in the same year, the fair value as of the vesting date ​ $ — ​ $ — ​ $ — ​ $ — $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For awards granted in prior years that vest in the fiscal year, the change in the fair value from the end of the prior fiscal year to the vesting date ​ $ (1,748,809) ​ $ (929,042) ​ $ — ​ $ (2,766,063) $ (1,028,465) ​ $ 581,885 ​ $ 107,259 "Compensation Actually Paid" ​ ​ (173,208) ​ ​ (50,500) ​ ​ 3,169,786 ​ ​ (2,484,140) ​ (324,022) ​ ​ 22,045,076 ​ ​ 5,003,997 ​ Column (h). Illustrates the value, as of the last day of the indicated fiscal year, of an investment of $100 in the Company’s common stock made on December 31, 2019. Column (i). Illustrates the value, as of the last day of the indicated fiscal year, of an investment of $100 in the NASDAQ Biotechnology Index made on December 31, 2019. Column (j) . Column (k) . At this time, given that we are a research and development company without revenue, we do not use any specific company-selected financial measures for purposes of determining “compensation actually paid.” As is the case with many companies in the biotechnology industry, our annual incentive objectives are generally tied to the Company’s strategic and operational goals rather than financial goals. However, our Compensation Committee has approved robust goals and objectives discussed annually in our Compensation Discussion and Analysis section in this proxy statement and the proxy statements reporting pay for the fiscal years covered in these tables. Accordingly, we do not have a financial metric in our executive compensation program that would constitute the Company Selected Measure, as contemplated under the SEC Pay Versus Performance disclosure rules. ​
Named Executive Officers, Footnote [Text Block]	Columns (b), (d) and (f) . Reflects compensation amounts reported in the “Summary Compensation Table” (“SCT”) for our CEOs and average amount reported for our non-CEO NEOs, for the respective years shown. Our CEOs and non-CEO NEOs for each of these fiscal years are shown below: Year CEO Non-CEO NEOs 2022 Frederick G. Vogt, Ph.D., J.D. Friedrich Graf Finckenstein, M.D., Jean-Marc Bellemin, Igor Bilinsky, Ph.D. 2021 ​ Frederick G. Vogt, Ph.D., J.D. (effective June 18, 2021), Maria Fardis, Ph.D. (until June 18, 2021) Friedrich Graf Finckenstein, M.D., Jean-Marc Bellemin, Igor Bilinsky, Ph.D., Michael Swartzburg 2020 ​ Maria Fardis, Ph.D. ​ Frederick G. Vogt, Ph.D., J.D (as General Counsel), Friedrich Graf Finckenstein, M.D., Jean-Marc Bellemin, Michael Swartzburg ​
Adjustment To PEO Compensation, Footnote [Text Block]	Columns (c), (e) and (g) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CAP ​ Average ​ CAP ​ CAP Average ​ CAP ​ Average ​ ​ Compensation ​ CAP ​ Compensation ​ Compensation CAP ​ Compensation ​ CAP ​ ​ for ​ Compensation ​ for ​ for Compensation ​ for ​ Compensation Adjustments CEO 1 for other NEOs CEO 1 CEO 2 for other NEOs CEO 2 for other NEOs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reported Summary Compensation Table Total ​ $ 5,259,100 ​ $ 2,159,230 ​ $ 3,216,310 ​ $ 7,011,698 $ 3,270,763 ​ $ 9,039,400 ​ $ 2,593,418 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deduction for amounts reported under Stock Awards and Option Awards columns in Summary Compensation Table for applicable fiscal year. ​ $ (3,872,500) ​ $ (1,185,030) ​ $ (2,463,502) ​ $ (6,729,775) $ (2,880,217) ​ $ (8,139,400) ​ $ (2,197,299) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Add back: The year-end fair value of any equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the fiscal year ​ $ 1,597,498 ​ $ 463,158 ​ $ 2,416,978 ​ $ — $ 1,548,311 ​ $ 17,391,380 ​ $ 3,771,653 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The change in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year ​ $ (1,408,496) ​ $ (558,816) ​ $ — ​ $ — $ (1,234,414) ​ $ 3,171,811 ​ $ 728,968 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For awards that are granted and vest in the same year, the fair value as of the vesting date ​ $ — ​ $ — ​ $ — ​ $ — $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For awards granted in prior years that vest in the fiscal year, the change in the fair value from the end of the prior fiscal year to the vesting date ​ $ (1,748,809) ​ $ (929,042) ​ $ — ​ $ (2,766,063) $ (1,028,465) ​ $ 581,885 ​ $ 107,259 "Compensation Actually Paid" ​ ​ (173,208) ​ ​ (50,500) ​ ​ 3,169,786 ​ ​ (2,484,140) ​ (324,022) ​ ​ 22,045,076 ​ ​ 5,003,997 ​
Non-PEO NEO Average Total Compensation Amount	$ 2,159,230	$ 3,270,763	$ 2,593,418
Non-PEO NEO Average Compensation Actually Paid Amount	$ (50,500)	(324,022)	5,003,997
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]	Columns (c), (e) and (g) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CAP ​ Average ​ CAP ​ CAP Average ​ CAP ​ Average ​ ​ Compensation ​ CAP ​ Compensation ​ Compensation CAP ​ Compensation ​ CAP ​ ​ for ​ Compensation ​ for ​ for Compensation ​ for ​ Compensation Adjustments CEO 1 for other NEOs CEO 1 CEO 2 for other NEOs CEO 2 for other NEOs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reported Summary Compensation Table Total ​ $ 5,259,100 ​ $ 2,159,230 ​ $ 3,216,310 ​ $ 7,011,698 $ 3,270,763 ​ $ 9,039,400 ​ $ 2,593,418 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deduction for amounts reported under Stock Awards and Option Awards columns in Summary Compensation Table for applicable fiscal year. ​ $ (3,872,500) ​ $ (1,185,030) ​ $ (2,463,502) ​ $ (6,729,775) $ (2,880,217) ​ $ (8,139,400) ​ $ (2,197,299) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Add back: The year-end fair value of any equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the fiscal year ​ $ 1,597,498 ​ $ 463,158 ​ $ 2,416,978 ​ $ — $ 1,548,311 ​ $ 17,391,380 ​ $ 3,771,653 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The change in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year ​ $ (1,408,496) ​ $ (558,816) ​ $ — ​ $ — $ (1,234,414) ​ $ 3,171,811 ​ $ 728,968 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For awards that are granted and vest in the same year, the fair value as of the vesting date ​ $ — ​ $ — ​ $ — ​ $ — $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For awards granted in prior years that vest in the fiscal year, the change in the fair value from the end of the prior fiscal year to the vesting date ​ $ (1,748,809) ​ $ (929,042) ​ $ — ​ $ (2,766,063) $ (1,028,465) ​ $ 581,885 ​ $ 107,259 "Compensation Actually Paid" ​ ​ (173,208) ​ ​ (50,500) ​ ​ 3,169,786 ​ ​ (2,484,140) ​ (324,022) ​ ​ 22,045,076 ​ ​ 5,003,997 ​
Compensation Actually Paid vs. Total Shareholder Return [Text Block]	​ ​ ​
Compensation Actually Paid vs. Net Income [Text Block]	​ ​ ​
Total Shareholder Return Vs Peer Group [Text Block]	​ ​ ​
Tabular List [Table Text Block]	​ Performance Measure Manage overall spending to within 5% of budget Maintain sufficient cash balance at year-end to successfully finance future operating activities and clinical development programs Appropriately and opportunistically finance the Company through various means including the use of an at-the market equity financing facility ​
Total Shareholder Return Amount	$ 23.08	68.95	167.61
Peer Group Total Shareholder Return Amount	113.65	126.45	126.42
Net Income (Loss)	$ (395,900,000)	(342,300,000)	(259,600,000)
PEO Name	Frederick G. Vogt, Ph.D., J.D.
Measure [Axis]: 1
Pay vs Performance Disclosure [Table]
Measure Name	Manage overall spending to within 5% of budget
Measure [Axis]: 2
Pay vs Performance Disclosure [Table]
Measure Name	Maintain sufficient cash balance at year-end to successfully finance future operating activities and clinical development programs
Measure [Axis]: 3
Pay vs Performance Disclosure [Table]
Measure Name	Appropriately and opportunistically finance the Company through various means including the use of an at-the market equity financing facility
Frederick G. Vogt
Pay vs Performance Disclosure [Table]
PEO Total Compensation Amount	$ 5,259,100	3,216,310
PEO Actually Paid Compensation Amount	(173,208)	3,169,786
Maria Fardis
Pay vs Performance Disclosure [Table]
PEO Total Compensation Amount		7,011,698	9,039,400
PEO Actually Paid Compensation Amount		(2,484,140)	22,045,076
PEO [Member] | Frederick G. Vogt | Deduction for amounts reported under Stock Awards and Option Awards columns in Summary Compensation Table for applicable fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(3,872,500)	(2,463,502)
PEO [Member] | Frederick G. Vogt | Add back: The year-end fair value of any equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	1,597,498	2,416,978
PEO [Member] | Frederick G. Vogt | The change in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(1,408,496)
PEO [Member] | Frederick G. Vogt | For awards granted in prior years that vest in the fiscal year, the change in the fair value from the end of the prior fiscal year to the vesting date
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(1,748,809)
PEO [Member] | Maria Fardis | Deduction for amounts reported under Stock Awards and Option Awards columns in Summary Compensation Table for applicable fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		(6,729,775)	(8,139,400)
PEO [Member] | Maria Fardis | Add back: The year-end fair value of any equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount			17,391,380
PEO [Member] | Maria Fardis | The change in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount			3,171,811
PEO [Member] | Maria Fardis | For awards granted in prior years that vest in the fiscal year, the change in the fair value from the end of the prior fiscal year to the vesting date
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		(2,766,063)	581,885
Non-PEO NEO [Member] | Deduction for amounts reported under Stock Awards and Option Awards columns in Summary Compensation Table for applicable fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(1,185,030)	(2,880,217)	(2,197,299)
Non-PEO NEO [Member] | Add back: The year-end fair value of any equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	463,158	1,548,311	3,771,653
Non-PEO NEO [Member] | The change in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(558,816)	(1,234,414)	728,968
Non-PEO NEO [Member] | For awards granted in prior years that vest in the fiscal year, the change in the fair value from the end of the prior fiscal year to the vesting date
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	$ (929,042)	$ (1,028,465)	$ 107,259